Business Development Insights: Panel discussion with industry experts

Поділитися
Вставка
  • Опубліковано 18 січ 2025
  • Panelists: Vanessa Barth, Lilly Gateway Labs; Mike Luther, STRM.BIO; David Rothkopf, MEDIcept
    This panel discussion brings expertise from different industry perspectives to answer questions about business development during product development. The panelists will describe what they look for in viable startups/products, appropriate timing for strategic partnering, and the benefits/risks of partnering with large pharma as a path to market. The first portion of this webinar will be moderated, followed by time reserved for live question and answer from the audience.
    Vanessa Barth, Ph.D. is Associate Vice President, COO & Head of Lilly Gateway Labs East Coast, and Site Head of Lilly Gateway Labs Boston Seaport location. Lilly Gateway Labs provides expertise and capabilities to accelerate drug discovery and development through early engagement with biotech companies and tailored support offerings. Complementing her position at Eli Lilly, Dr. Barth helped establish the AXIS mentoring program at the Indiana Biosciences Research Institute to advise and mentor life sciences entrepreneurs. Dr. Barth earned her PhD in Medical Neurobiology from Indiana University.
    Mike Luther, Ph.D. is an experienced entrepreneurial scientist and executive in the biopharmaceutical industry including various senior leadership roles ranging from biotech start-ups to global pharmaceutical companies and CROs. In addition to serving as STRM.BIO's CEO, he is currently the managing partner for BioInnovations, LLC where he is a board member and consultant for various start up biotech companies.
    David Rothkopf, Ph.D. is a strategic professional in the development and regulatory control of medical devices. He is the President and Co-Founding Principal at MEDIcept; established in 1996 to offer engineering, manufacturing, quality, and regulatory consulting assistance to the medical device and IVD industry.
    In addition to being President of MEDIcept Inc., David is President of SON Medical, a medical software consulting firm and has been instrumental in starting three medical device companies.
    This webinar was presented on September 12, 2024 to an invited audience.
    This video is for educational purposes only.
    The Catalyze program utilizes a new approach to translational research by supporting both the technical needs of an innovation and the management, commercialization, regulatory, and training requirements of the innovators developing them. Projects supported by Catalyze receive funding and advisory support through the National Heart, Lung, and Blood Institute (NHLBI), as well as project management assistance, access to technical services and expertise, and training opportunities through the Catalyze Coordinating Center.
    This research was funded, in part, by the National Institutes of Health (NIH) Agreement OT2 HL157844-01. The views and conclusions of the presenters are their own and should not be interpreted as representing the official policies, either expressed or implied, of the NIH.
    NHLBI Catalyze Public Site: nhlbicatalyze.org

КОМЕНТАРІ •